- With a loss of over a third of the value, IMV Inc. (NASDAQ:IMV +18.8%) was a laggard among micro-cap healthcare stocks last week.
- Meanwhile, citing “significant potential upside from the current price,” Wells Fargo has resumed the coverage of IMV with an overweight rating.
- The price target of $14 implies a premium of ~914.5% to Thursday’s close, and on Friday the company shares recorded the biggest one-day gain since July 2020.
- The analysts point to a series of potentially value-generating events in the near term for the vaccine candidate maveropepimut-S, including an update on the program targeting ovarian cancer, which could inform a registrational trial likely to start in year-end 2021.
- Additionally, an investigator-initiated study of maveropepimut-S in breast cancer is on track for initiation in Q3 2021, IMV said, giving an update on its upcoming milestones in May.